Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | HPGDS | O60760 | 2/20 | 0.67 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NNMT | P40261 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586559 | 1.00 | LDHA (0.73) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5010814 | 0.98 | LDHA (0.71) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 | |
| SCHEMBL1758258 | 0.96 | LDHA (0.69) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 | |
| SCHEMBL1758318 | 0.86 | HPGDS (0.56) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 | |
| SCHEMBL1758435 | 0.86 | PARP10 (0.63) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 | |
| SCHEMBL505455 | 0.85 | LDHA (1.00) | LDHAHPGDSBAZ2BSMN1; SMN2P4HA1 | |
| SCHEMBL27584594 | 0.85 | LDHA (0.79) | LDHAHPGDSBAZ2BCYP11B1CYP11B2 | |
| SCHEMBL29915944 | 0.84 | MKNK1 (0.68) | LDHAHPGDSFYNSMN1; SMN2NNMT | |
| SCHEMBL22578364 | 0.84 | MKNK1 (0.68) | LDHAHPGDSFYNSMN1; SMN2NNMT | |
| SCHEMBL19581478 | 0.84 | NNMT (0.65) | LDHAHPGDSSMN1; SMN2NNMTMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029148-A | N-phenyl-3- (2, 5-dioxopyrrolidin-1-yl) propionamide derivatives and similar compounds as DUX4 inhibitors for the treatment of, for example, neuromuscular diseases | 阿勒泰治疗公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4628487-A2 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | Emory University (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-3941916-B1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | UNIV EMORY (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250206721-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, and Uses Related Thereto | UNIV EMORY (US) | 2025-06-26 | — | — | US | disclosed |
| US-12240829-B2 | Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| CN-117362276-A | Tropomyosin receptor kinase A inhibitor and preparation method and application thereof | 复旦大学 | 2024-01-09 | — | — | CN | disclosed |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| EP-3941916-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | Emory University (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020191208-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2020-09-24 | — | — | WO | disclosed |
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8440417-B2 | Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2286221-A2 | METHODS FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Cayman Chemical Company (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009140364-A2 | METHODS FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20060287378-A1 | Novel pyrroles and imidazoles | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20050239857-A1 | Novel imidazoles | BOLTON GARY L | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287378-A1 | Novel pyrroles and imidazoles | PPIP5K2, PPIE, PPOX | LDHA 3366/4885HPGDS 55/4885BAZ2B 1433/4885 |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | PTGER2, PTGES2, PTGES | LDHA 3724/4885HPGDS 63/4885BAZ2B 2318/4885 |
| US-20050239857-A1 | Novel imidazoles | HMGCR, HMGB2, HMGB3 | LDHA 779/4885HPGDS 39/4885BAZ2B 1730/4885 |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, HPGD, GMDS | LDHA 1557/4885HPGDS 1/4885BAZ2B 2454/4885 |
| US-12240829-B2 | Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto | PTGER2, PTGES2, PTGES | LDHA 3724/4885HPGDS 63/4885BAZ2B 2318/4885 |
| US-20250206721-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | LDHA 2909/4885HPGDS 47/4885BAZ2B 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.